Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer.

There was no significant difference in toxicity leading to treatment discontinuation between the poor and good PS groups, but survival was shorter with poorer PS. PS appears to be an important prognostic factor and remains a relevant discriminator in the selection of treatment with immunotherapy for lung cancer.